In the warning letter, the FDA alleged that Novo inadequately responded to observations made after an inspection carried out across January and February of 2025.
The leadership changes arrive as BioNTech reported a 57% rise in net losses for 2025.
The investment in China follows similar outlays by the drugmaker in other regions as it prepares for high orforglipron demand.
Neupharma will fund and conduct a pivotal clinical trial in Japan to support regulatory approval.
The new arrangement builds upon the existing mpox vaccine licence and manufacturing partnership between the two companies.
Ryan Rotar, vice president of healthcare market strategy at Tecsys, outlines how supply chain resilience can be maintained in the face of tariffs.
